Raphael E. Szalat, MD, PhD
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Hematology & Oncology

MD, Université Paris-Sorbonne, Paris IV
PhD, Université Paris-Sorbonne, Paris IV

Pronouns: he/him/his



I received my medical training at the University of Pierre and Marie Curie, in Paris, France. After Internal Medicine residency, I specialized in Immunology and plasma cell disorders including multiple myeloma and monoclonal gammopathies of clinical significance and became a clinical assistant professor in the department of Immuno-Hematology in Saint-Louis hospital, Paris. I next completed a PhD and post-doc in hematology studying genomics in Multiple Myeloma at the Dana-Farber Cancer Institute, Harvard Medical School in collaboration with La Sorbonne University, Paris and a clinical fellowship in Hematology and Oncology at the Boston University Medical Center. I am currently the multiple myeloma program director and the Stem Cell Transplant director at the Boston University Medical Center. My main interests are to develop myeloma clinical trials and to perform basic and translational research on multiple myeloma and other plasma cell disorders including AL amyloidosis and other monoclonal gammopathy of clinical significance.

Diversity, Equity, Inclusion and Accessibility

I am committed to promoting diversity and inclusion in academia and medicine. I have actively participated to all the Hematology and Medical Oncology section Diversity, Equity and Inclusions workshops. I participated to the LIFT Bystander Training for Microaggressions Workshops and to all other workshops proposed by our section. I am very attached to “medical” Justice and I am working on improving equal access to education, information and treatment of plasma cell disorders. To do so, I am leading the effort to develop a BU-CME interactive program addressing how to overcome barriers to effective treatment and enrollment in clinical trials of Afro-Americans and underserved patients.



CA088-1007
09/15/2025 - 09/14/2028 (PI)
Juno Therapeutics Inc.

KT-US-679-0788: A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
11/15/2024 - 11/14/2027 (PI)
Kite Pharma, Inc


64007957MMY3006 (MajesTEC-9)
09/12/2023 - 09/11/2026 (PI)
Janssen Research and Development, LLC


64407564MMY3002
05/05/2023 - 05/04/2026 (PI)
Janssen Research and Development, LLC


TAK-573-1501: A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
11/30/2022 - 11/29/2025 (PI)
Takeda Pharmaceuticals


Molecular characterization and therapeutic targeting of Protein Kinase D 2 in t(4;14) Multiple Myeloma
05/01/2021 - 12/01/2024 (PI)
International Myeloma Society



Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Muchtar E, Palladini G, Schonland S, Geyer S, Dooley KE, Dispenzieri A, Wisniowski B, Merlini G, Milani P, Hegenbart U, Dittrich T, Kastritis E, Dimopoulos MA, Sanchorawala V, Szalat R, Liedtke M, Gupta M, Landau H, Lentzsch S, Hughes MS, Cibeira MT, Blade J, Kumar SK, Wechalekar A, Gertz MA. Hepatic response criteria in light chain amyloidosis: a multicenter validation study. Haematologica. 2026 Jan 15.View Related Profiles. PMID: 41537335
     
  2. Fulciniti M, Yao Y, Perini T, Fong Ng J, Schavgoulidze A, Deng S, Cui J, Encinas Mayoral J, Ladisa F, Young RM, Epstein CB, White CM, Ott CJ, Gulla A, Matulis SM, Sperling AS, Morelli E, Boise LH, Binder M, Szalat R, Samur MK, Anderson KC, Munshi NC. ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3. Blood Cancer Discov. 2026 Jan 12; 7(1):129-141.View Related Profiles. PMID: 41104834; PMCID: PMC12616536; DOI: 10.1158/2643-3230.BCD-25-0048;
     
  3. Ferri GM, Martinez CB, Acevedo J, Bhatt S, Verma KP, Lee J, Abdallah M, Szalat RE, Sloan JM. Exploring the effect of Duffy status on patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors. Breast Cancer Res Treat. 2025 Dec 12; 215(1):36.View Related Profiles. PMID: 41385110
     
  4. Aktas Samur A, Corre J, Talluri S, Shah P, Graffeuil A, Rivera J, Fan Y, Dakiki Korucu B, Szalat R, Fulciniti M, Anderson KC, Sperling A, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK. Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma. J Clin Oncol. 2026 Feb; 44(4):321-334.View Related Profiles. PMID: 41380103
     
  5. Holder EX, Szalat R, Palmer JR, Bertrand KA. Neighborhood disadvantage and multiple myeloma incidence in the Black Women's Health Study. Int J Epidemiol. 2025 Oct 14; 54(6).View Related Profiles. PMID: 41206638; PMCID: PMC12596579; DOI: 10.1093/ije/dyaf188;
     
  6. Cetin O, Staron A, Teodorescu P, Sloan JM, Sanchorawala V, Szalat R. Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis-Related Acquired Factor X Deficiency. Am J Hematol. 2025 Dec; 100(12):2416-2420.View Related Profiles. PMID: 40981270
     
  7. Ferri GM, Frank A, Li D, Anand P, Abdallah M, Avalone V, Mark Sloan J, Sanchorawala V, Lerner A, Szalat RE, Petrocca F, Edwards CV, Bell BN. When ICAN(S) Becomes ICAN'T: Clinician and Staff Perspectives on In-Hospital Neurotoxicity Grading. Clin Lymphoma Myeloma Leuk. 2026 Jan; 26(1):e77-e82.View Related Profiles. PMID: 41015712; DOI: 10.1016/j.clml.2025.08.021;
     
  8. Battaglini J, Henderson J, Sanchorawala V, Szalat R. Teclistamab therapy for refractory type 1 cryoglobulinemia. Haematologica. 2025 Aug 01; 110(8):1891-1893.View Related Profiles. PMID: 40109179; PMCID: PMC12358774; DOI: 10.3324/haematol.2025.287313;
     
  9. Abdallah M, Arters F, Patel J, Edwards C, Lerner A, Petrocca F, Dockerty M, Fuller B, Godfrey A, Staron A, Sanchorawala V, Sloan JM, Bertrand K, Szalat R. Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosis. Blood Adv. 2024 Dec 10; 8(23):5935-5938.View Related Profiles. PMID: 39348709; PMCID: PMC11629209; DOI: 10.1182/bloodadvances.2024013453;
     
  10. Muchtar E, Wisniowski B, Geyer S, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Leung N, Dispenzieri A, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Ulloa P, Sanchorawala V, Szalat R, Dooley K, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Gillmore J, Lachmann H, Wechalekar A, Gertz MA. Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis. JAMA Oncol. 2024 Oct 01; 10(10):1362-1369.View Related Profiles. PMID: 39088206; PMCID: PMC11295065; DOI: 10.1001/jamaoncol.2024.2629;
     
Showing 10 of 65 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 65 publications over 18 distinct years, with a maximum of 7 publications in 2021

YearPublications
20091
20101
20111
20121
20131
20143
20154
20166
20176
20186
20194
20203
20217
20224
20233
20246
20256
20262


2021-2022 International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Translational Resear
2016-2017 NIH grant (4P50CA100707-14) to investigate the impact of bone marrow microenvironment on multiple my
2013-2014 French foundation for the research on multiple myeloma and gammopathies award
2010 Paris University: Medical thesis Congratulated with Distinctions and Silver Medal, Xanthomatosis and Monoclonal Immuno
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Monoclonal Gammopathy of clinical significance
Multiple Myeloma
Plasma cell disorder
MGUS
Genomics
Epigenomics

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
  • Work / Life Integration Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

650 Albany St
Boston MA 02118
Google Map

617.638.7518
Download vCard

Szalat's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (260) concept(s)
_
Co-Authors
See all (30) people
_
Similar People
See all (60) people
_
Same Department
Search Department